Oruka Therapeutics Inc. Common Stock
ORKAUnited States
61 filed reports · 438 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
61 reports · Jun 2011 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 46 | 4,069 | Jun 2011 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 15 | 3,218 | Dec 2011 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 10, 2026 | 233 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 13, 2026 | 126 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 12, 2026 | 280 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 12, 2025 | 131 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 90 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 14, 2025 | 84 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 6, 2025 | 44 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 13, 2024 | 77 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 158 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | Apr 25, 2024 | 95 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 1, 2024 | 320 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Oct 18, 2023 | 109 | Open |
Financial data
438 concepts · 7,287 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial438 concepts · 7,287 facts · Dec 2003 to Jun 2026
- Stockholders equity (US GAAP)91 · Dec 2003 to Jun 2026
- Net income loss85 · Dec 2004 to Jun 2026
- Cash and cash equivalents at carrying value83 · Dec 2009 to Jun 2026
- Share based compensation82 · Dec 2006 to Jun 2026
- Operating expenses (US GAAP)79 · Jun 2010 to Jun 2026
- Operating income loss79 · Jun 2010 to Jun 2026
- Research and development expense79 · Jun 2010 to Jun 2026
- Assets78 · Dec 2010 to Jun 2026
- Assets current78 · Dec 2010 to Jun 2026
- Common stock par or stated value per share78 · Dec 2010 to Jun 2026
- Common stock shares authorized78 · Dec 2010 to Jun 2026
- Common stock shares issued78 · Dec 2010 to Jun 2026
- Common stock shares outstanding78 · Dec 2010 to Jun 2026
- Common stock value78 · Dec 2010 to Jun 2026
- Liabilities and stockholders equity78 · Dec 2010 to Jun 2026
- Liabilities current78 · Dec 2010 to Jun 2026
- Other assets noncurrent78 · Dec 2010 to Jun 2026
- Property plant and equipment net78 · Dec 2010 to Jun 2026
- Retained earnings accumulated deficit78 · Dec 2010 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding number75 · Dec 2010 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding weighted average exercise price75 · Dec 2010 to Jun 2026
- Allocated share based compensation expense74 · Jun 2011 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value72 · Dec 2006 to Jun 2026
- Liabilities71 · Dec 2010 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary19 claims from 2 reports · Jun 2024 to Jun 2026
- Management discussion (MD&A) commentary155 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes26 claims from 1 reports · Dec 2025
- Risk factors123 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.